Phase II studies of anticancer chemotherapy: Indirect evidence of poor quality [7]

Annals of Oncology

Volumn 18, Issue 2, 2007, Pages 403-

  Ottaiano, Ale ^a   Facchini, G ^a   Nasti, G ^a   Budillon, A ^a   Caraglia, M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CYTOKINE;

BIOLOGICAL THERAPY; BIOSTATISTICS; CANCER CHEMOTHERAPY; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; HUMAN; LETTER; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; SCISEARCH;

ANTINEOPLASTIC AGENTS; BIBLIOMETRICS; CLINICAL TRIALS, PHASE II; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; PUBLISHING;

EID: 33847308541     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl402     Document Type: Letter

References (5)

1. Ottaiano A, Mollo E, Di Lorenzo G et al. Prospective clinical trials of biotherapies in solid tumors: A 5-year survey. Cancer Immunol Immunother 2005; 54: 44-50.
2. Ottaiano A, Castello G, Ascierto PA. Evidence of publication bias in clinical trials of biotherapies for solid tumors. Cancer 2005; 103: 653.
3. Kramar A, Potvin D, Hill C. Multistage designs for phase II clinical trials: Statistical issues in cancer research. Br J Cancer 1996; 74: 1317-1320.
4. Mariani L, Marubini E. Content and quality of currently published phase II cancer trials. J Clin Oncol 2000; 18: 429-436.
5. Perrone F; Di Maio M, De Maio E et al. Statistical design in phase II clinical trials and its application in breast cancer. Lancet Oncol 2003; 4: 305-311.